Fig. 5: T-cell activation and T-cell-mediated cell killing by AlproTox. | British Journal of Cancer

Fig. 5: T-cell activation and T-cell-mediated cell killing by AlproTox.

From: Identification of a high-risk immunogenic prostate cancer patient subset as candidates for T-cell engager immunotherapy and the introduction of a novel albumin-fused anti-CD3 × anti-PSMA bispecific design

Fig. 5

An increasing dose of tested AlproTox fusion was co-incubated with Jurkat cells and PC cell lines (PSMA-positive closed symbols, PSMA negative open symbols) followed by flow cytometry analysis quantifying the expression of CD69 (a–c) Cell killing was quantified using an LDH-endpoint assay determining the percentage of lysed PC cell lines when co-incubated with increasing levels of AlproTox and isolated PBMCs (d–f). Statistical analysis was made in Graphpad prism v.8 with Mean ± SEM shown, N = 3 independent experiments, (LNCaP N = 2 independent experiments).

Back to article page